{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:11:55Z","timestamp":1790007115923,"version":"4.0.1"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100022840","name":"Serum Institute of India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022840","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.vaccine.2026.128481","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T07:41:39Z","timestamp":1773819699000},"page":"128481","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Pharmacovigilance capacity and readiness of vaccine manufacturers in low- and middle-income countries: a maturity-based assessment of the pharmacovigilance system"],"prefix":"10.1016","volume":"79","author":[{"given":"Patricia Mouta Nunes","family":"de Oliveira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Bosman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Beatriz Bastos","family":"Lucchesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Comfort","family":"Ogar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata Sariva","family":"Pedro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128481_bb0005","series-title":"Definition and application of terms for vaccine pharmacovigilance: Report of CIOMS\/WHO working group on vaccine pharmacovigilance","author":"Council for International Organizations of mMedical sSciences (CIOMS)","year":"2012"},{"key":"10.1016\/j.vaccine.2026.128481_bb0010","unstructured":"World Health Organization (WHO). Global vaccine safety blueprint (GVSB). WHO\/IVB\/12.07. Geneva: WHO; 2012."},{"key":"10.1016\/j.vaccine.2026.128481_bb0015","series-title":"WHO Global Benchmarking Tool (GBT) for evaluation of national regulatory system of medical products","author":"World Health Organization (WHO)","year":"2018"},{"key":"10.1016\/j.vaccine.2026.128481_bb0020","unstructured":"World Health Organization (WHO). WHO Global Benchmarking Tool (GBT) for evaluation of national regulatory system of medical products. 2021. Available from: https:\/\/www.who.int\/tools\/global-benchmarking-tools\/VI Accessed 2025 Nov 24."},{"key":"10.1016\/j.vaccine.2026.128481_bb0025","unstructured":"World Health Organization (WHO). Global Vaccine Safety Blueprint 2.0 (GVSB 2.0) 2021\u20132023. 2021. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240036963. Accessed 2025 Nov 24."},{"key":"10.1016\/j.vaccine.2026.128481_bb0030","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2174\/0115748863276456231016062628","article-title":"Awareness of pharmacovigilance among healthcare professionals due to underreporting of adverse drug reactions: a systematic review of the current state, obstacles, and strategy","volume":"19","author":"Putri","year":"2024","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.vaccine.2026.128481_bb0035","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/bcp.15193","article-title":"Pharmacovigilance in low- and middle-income countries: a review with particular focus on Africa","volume":"89","author":"Kiguba","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.vaccine.2026.128481_bb0040","doi-asserted-by":"crossref","unstructured":"Guzman J, O'Connell E, Kikule K, Hafner TZ. The WHO global benchmarking tool: a game changer for strengthening national regulatory capacity. BMJ Glob Health 2020;5:e003181. Available from: https:\/\/gh.bmj.com\/content\/5\/8\/e003181 Accessed 2025 Nov 24.","DOI":"10.1136\/bmjgh-2020-003181"},{"key":"10.1016\/j.vaccine.2026.128481_bb0045","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.1016\/j.vaccine.2020.06.016","article-title":"Landscape analysis of pharmacovigilance and related practices among 34 vaccine manufacturers from emerging countries","volume":"38","author":"Hartmann","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128481_bb0050","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s43441-022-00415-y","article-title":"A systematic review of pharmacovigilance systems in developing countries using the WHO pharmacovigilance indicators","volume":"56","author":"Garashi","year":"2022","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.vaccine.2026.128481_bb0055","doi-asserted-by":"crossref","unstructured":"Menang O, van Eeuwijk P, Maigetter K, et al. Pharmacovigilance processes in low- and middle-income countries: moving from data collection to data analysis and interpretation. Ther Adv Drug Saf 2025 Jun 10;16:20420986251342941. Available from: https:\/\/pmcncbinlmnihgov\/articles\/PMC12185949\/ Accessed 2025 Nov 24.","DOI":"10.1177\/20420986241300006"},{"key":"10.1016\/j.vaccine.2026.128481_bb0060","doi-asserted-by":"crossref","unstructured":"Beninger P, Caubel P, Sharma L, et al. Effects of the COVID-19 pandemic on pharmacovigilance strategy, systems, and processes of large, medium, and small companies: an industry survey. Clin Ther 2022;44:1225\u20131236. doi:10.1016\/j.clinthera.2022.07.007. Accessed 2025 Nov 25.","DOI":"10.1016\/j.clinthera.2022.07.007"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26002896?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26002896?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:49:47Z","timestamp":1781308187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26002896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":12,"alternative-id":["S0264410X26002896"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128481","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacovigilance capacity and readiness of vaccine manufacturers in low- and middle-income countries: a maturity-based assessment of the pharmacovigilance system","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128481","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"128481"}}